Amprius Secures $21M China EV Order, But Execution Risks Overshadow Growth Signal

What happened

Amprius Technologies announced a $21 million purchase order from a new Chinese electric mobility customer for its SiCore batteries in light vehicles like scooters and three-wheelers, highlighting demand expansion beyond its core UAS and defense markets. This news arrives as the company scales via contract manufacturing to meet aggressive FY2026 guidance of over $125 million in revenue and positive adjusted EBITDA, following a strong Q4'25 with $25.2 million revenue and 24% gross margin. However, the DeepValue master report rates AMPX as 'WAIT' with conviction 4.0, citing critical risks such as limited visibility into partner economics, a $13.8 million deferred-tax valuation allowance increase signaling profitability doubts, and insider selling patterns that create equity overhang. The report emphasizes that the next 1-2 quarters must validate the sustainability of this revenue run-rate and margin durability, with failure points including gross margin reversion or shipment delays. While this order adds to backlog, it does not address the core need for quantified partner performance data or alleviate concerns about Amprius's ability to convert orders into consistent, profitable deliveries.

Implication

The $21 million order demonstrates Amprius's ability to attract new customers in the electric mobility sector, potentially diversifying revenue streams and supporting near-term shipment growth. However, it fails to mitigate the report's highlighted risks: contract manufacturing yields and costs remain unquantified, leaving gross margin sustainability uncertain despite the Q4'25 step-up to 24%. Investors must monitor whether this order converts into steady quarterly revenue without margin erosion, as the report's base case of $125 million FY2026 revenue relies on such execution, while the bear case of $90 million looms if conversion slips. Additionally, the equity overhang from resale registrations and insider selling could pressure the stock price, independent of operational progress. Therefore, this news alone is insufficient to alter the 'WAIT' rating, and investors should await Q1-Q2'26 results for proof of scalable profitability before considering entry.

Thesis delta

The new order provides incremental evidence of demand but does not shift the core investment thesis, which remains centered on validating scalable and profitable operations through contract manufacturing. Key uncertainties persist, including gross margin durability and revenue conversion consistency, with no material change warranted until upcoming quarterly reports confirm execution against FY2026 guidance. The thesis delta is minimal, reinforcing the need for patience rather than prompting a re-rating.